评估抗真菌药物处方的适宜性:澳大利亚医院新型审计工具实施的关键结果
该研究利用抗真菌国家抗菌药物处方调查(Antifungal NAPS)工具,评估澳大利亚11家医院516张系统性抗真菌处方的质量。结果显示77.1%处方适宜,预防性用药适宜率最高(85.1%),经验性治疗最低(63.4%);氟康唑处方最常见但适宜率最低(63.2%)。不适宜处方最常见原因为无需抗真菌药物(33.3%)、剂量或频率错误(28.6%)及疗程错误(18.1%),指南依从率为73.6%。
要点
- 预防性抗真菌处方适宜率最高(189/222;85.1%),经验性治疗适宜率最低(104/164;63.4%)。
- 氟康唑是最常见处方药物,但适宜率最低(132/209;63.2%)。
- 不适宜处方主要原因为无需抗真菌药物(35/105;33.3%)和剂量或频率错误(30/105;28.6%)。
核心结论
- 本研究描述了抗真菌NAPS这一标准化电子审计工具的成功实施,该工具用于评估抗真菌处方质量。
- 识别的质量改进关键领域包括:经验性氟康唑用于尿路和腹腔感染的过度使用、侵袭性真菌感染风险评估对指导预防性处方的的重要性,以及加强感染病和抗真菌管理对於抗真菌处方的监督以指导最佳处方。
研究设计与样本
- 参与医院被指导审计所有系统性抗真菌药物或聚焦于特定抗真菌药物或类别。
- 数据录入抗真菌NAPS在线门户的时间为2022年10月至2023年6月。
- 数据收集工具包括患者详情、妨碍使用抗真菌药物的原因、处方详情(指南依从性、适宜性及不适宜处方的原因)和患者结局。
- 采用描述性统计进行数据分析。
- 11家医院提供了438名患者的516张处方的数据。
主要发现
- 77.1%的处方为适宜。
- 预防性用药适宜率最高(189/222;85.1%),其次为针对性治疗(105/130;80.8%)和经验性治疗(104/164;63.4%)。
- 氟康唑是最常处方的药物,其适宜率最低(132/209;63.2%)。
- 不适宜处方最常见原因为无需抗真菌药物(35/105;33.3%)、剂量或频率错误(30/105;28.6%)和疗程错误(19/105;18.1%)。
- 指南依从率为73.6%。
临床怎么用
- 本研究未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To utilize the Antifungal National Antimicrobial Prescribing Survey (Antifungal NAPS), a novel tool utilizing international consensus metrics for antifungal stewardship, to assess the quality of systemic antifungal prescribing in Australian hospitals, in order to identify quality improvement targets. METHODS: Participating hospitals were directed to audit all systemic antifungals or focus on a specific antifungal drug or class. Data entry into the Antifungal NAPS online portal occurred between October 2022 and June 2023. The data collection tool comprised patient details, reasons precluding use of antifungals, prescription details (guideline compliance, appropriateness, and reasons for inappropriate prescribing) and patient outcomes. Descriptive statistics were used to analyse the data. RESULTS: Eleven hospitals contributed data for 516 prescriptions for 438 patients. Of these, 77.1% of prescriptions were appropriate, with the highest appropriateness for prophylactic (189/222; 85.1%), followed by directed (105/130; 80.8%) and empirical therapy (104/164; 63.4%). Fluconazole was the most commonly prescribed agent, which had the lowest rate of appropriateness (132/209; 63.2%). The most common reasons for inappropriate prescribing were no antifungal required (35/105; 33.3%), incorrect dose or frequency (30/105; 28.6%) and incorrect duration (19/105; 18.1%). Compliance with guidelines was 73.6%. CONCLUSIONS: This study outlines the successful implementation of the Antifungal NAPS, a standardized electronic audit tool for the assessment of antifungal prescribing quality. Key areas for quality improvement identified were the overuse of empirical fluconazole for urinary tract and intra-abdominal infections, the importance of invasive fungal infection risk assessment to guide prophylaxis prescribing and greater infectious diseases and antifungal stewardship oversight of antifungal prescribing to guide optimal prescribing.
引用
- Khanina A, Singh N, James R, et al. Assessing the appropriateness of antifungal prescribing: key results from the implementation of a novel audit tool in Australian hospitals. J Antimicrob Chemother. 2025. PMID: 39945054. doi:10.1093/jac/dkaf044
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。